Blog

  • Roger Godsiff – 2015 Parliamentary Question to the Department of Health

    Roger Godsiff – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2015-02-20.

    To ask the Secretary of State for Health, what steps he plans to take to ensure that patients who have opted out of the care.data scheme with a type 2 objection will not be excluded from NHS services such as bowel screening and e-referrals.

    Dr Daniel Poulter

    The process for objecting (‘opting out’) will be communicated during the care.data pathfinder stage and will apply to the use of identifiable general practitioner data for purposes beyond direct care. The care.data Programme team is working closely with clinical commissioning group pathfinder practices to ensure that it is understood that the opt-out should not impact upon the sharing of information for direct care.

    The care.data Programme team is working closely with the Health and Social Care Information Centre (HSCIC), NHS England and the Department in relation to ‘type 2 objections’. Appropriate communications will be agreed before starting communication activity in pathfinder areas.

    For those people who have made an existing ‘type 2 objection’, the HSCIC is committed to ensuring no patient suffers any adverse impact on their direct care through an inappropriate implementation of an objection. This means that information flows to support services such as cancer screening, electronic prescriptions and e-referrals are currently flowing and will continue to do so.

  • Roger Godsiff – 2015 Parliamentary Question to the Department of Health

    Roger Godsiff – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2015-02-20.

    To ask the Secretary of State for Health, what steps he plans to take to ensure that patients who opt-out of the care.data programme are not excluded from certain NHS services before that programme is fully implemented.

    Dr Daniel Poulter

    The process for objecting (‘opting out’) will be communicated during the care.data pathfinder stage and will apply to the use of identifiable general practitioner data for purposes beyond direct care. The care.data Programme team is working closely with clinical commissioning group pathfinder practices to ensure that it is understood that the opt-out should not impact upon the sharing of information for direct care.

    The care.data Programme team is working closely with the Health and Social Care Information Centre (HSCIC), NHS England and the Department in relation to ‘type 2 objections’. Appropriate communications will be agreed before starting communication activity in pathfinder areas.

    For those people who have made an existing ‘type 2 objection’, the HSCIC is committed to ensuring no patient suffers any adverse impact on their direct care through an inappropriate implementation of an objection. This means that information flows to support services such as cancer screening, electronic prescriptions and e-referrals are currently flowing and will continue to do so.

  • Roger Godsiff – 2015 Parliamentary Question to the Department of Health

    Roger Godsiff – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2015-02-20.

    To ask the Secretary of State for Health, with reference to his Department’s leaflet Better information means better care, published January 2014, and the oral evidence to the Health Committee of Dame Fiona Caldicott, 21 January 2015 to Question 705, what steps he is taking to ensure that if patients choose to opt out of care.data this will not have any adverse effect on (a) bowel screening, (b) e-referrals and (c) other services.

    Dr Daniel Poulter

    The process for objecting (‘opting out’) will be communicated during the care.data pathfinder stage and will apply to the use of identifiable general practitioner data for purposes beyond direct care. The care.data Programme team is working closely with clinical commissioning group pathfinder practices to ensure that it is understood that the opt-out should not impact upon the sharing of information for direct care.

    The care.data Programme team is working closely with the Health and Social Care Information Centre (HSCIC), NHS England and the Department in relation to ‘type 2 objections’. Appropriate communications will be agreed before starting communication activity in pathfinder areas.

    For those people who have made an existing ‘type 2 objection’, the HSCIC is committed to ensuring no patient suffers any adverse impact on their direct care through an inappropriate implementation of an objection. This means that information flows to support services such as cancer screening, electronic prescriptions and e-referrals are currently flowing and will continue to do so.

  • Robert Flello – 2015 Parliamentary Question to the Department of Health

    Robert Flello – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Flello on 2015-02-20.

    To ask the Secretary of State for Health, pursuant to the Answer of 10 February 2015 to Question HL4441, whether the Human Fertilisation and Embryology Authority imposed sanctions on clinics that had administered reagents to permitted gametes or permitted embryos that are then introduced into patients when the reagents concerned had not been CE marked; and when the Medicines and Healthcare products Regulatory Agency was notified of such instances documented in inspection reports.

    Jane Ellison

    The Human Fertilisation and Embryology Authority has advised that it has not been necessary to impose any regulatory sanctions in relation to the use of non CE marked reagents or products, as the clinics in question have given a commitment, as part of the inspection process, to use alternative CE marked products. The Medicines and Healthcare products Regulatory Agency is not notified of individual instances as reported in inspection reports, as its responsibilities relate to the manufacturers of these products not the users.

  • Robert Flello – 2015 Parliamentary Question to the Department of Health

    Robert Flello – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Flello on 2015-02-20.

    To ask the Secretary of State for Health, whether his Department has made an estimate of the change in the number of donor eggs that will be required by the authorisation of mitochondrial donation.

    Jane Ellison

    I refer the hon. Member to the answer I gave to the hon. Member for North Tyneside (Mrs Mary Glindon) to PQ 208397 on 11 September 2014.

    “

  • Wayne David – 2015 Parliamentary Question to the Department of Health

    Wayne David – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Wayne David on 2015-02-20.

    To ask the Secretary of State for Health, what steps his Department is taking to implement the recommendations of the Lancet Commission report on liver disease, published on 27 November 2014.

    Jane Ellison

    Whilst NHS England is responsible for the overall national approach to improving clinical outcomes for people with liver disease, Public Health England (PHE) is working with the Lancet Commission on Liver Disease. This work involves regular meetings with Professor Richard Williams, (Lead, Lancet Standing Commission into Liver Disease in the UK), and attending action planning meetings.

    PHE is working with NHS England and liver charities to respond to the key recommendations of the Lancet Commission and will produce a Liver Disease Framework in summer 2015 outlining the scope of its activities.

    This will cover PHEs extensive programme of activities to tackle the three main risk factors for liver disease: alcohol, obesity and Hepatitis B & C; work with the Lancet Commissioners and GPs to strengthen detection and interventions for early stage liver disease and for identification of high risk patients; support a national needs assessment for liver disease services in the NHS.

  • Wayne David – 2015 Parliamentary Question to the Department of Health

    Wayne David – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Wayne David on 2015-02-20.

    To ask the Secretary of State for Health, for what reasons the strategy for combating liver disease referred to by the Prime Minister on the 10 Downing Street website on 28 July 2011 has not been published.

    Jane Ellison

    Whilst NHS England is responsible for the overall national approach to improving clinical outcomes for people with liver disease, Public Health England (PHE) is working with the Lancet Commission on Liver Disease. This work involves regular meetings with Professor Richard Williams, (Lead, Lancet Standing Commission into Liver Disease in the UK), and attending action planning meetings.

    PHE is working with NHS England and liver charities to respond to the key recommendations of the Lancet Commission and will produce a Liver Disease Framework in summer 2015 outlining the scope of its activities.

    This will cover PHEs extensive programme of activities to tackle the three main risk factors for liver disease: alcohol, obesity and Hepatitis B & C; work with the Lancet Commissioners and GPs to strengthen detection and interventions for early stage liver disease and for identification of high risk patients; support a national needs assessment for liver disease services in the NHS.

  • Wayne David – 2015 Parliamentary Question to the Department of Health

    Wayne David – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Wayne David on 2015-02-20.

    To ask the Secretary of State for Health, what steps his Department is taking to improve diagnosis of hepatic encephalopathy.

    Jane Ellison

    Hepatic encephalopathy is an important end stage complication of liver disease. Monitoring at a national level is difficult because there is no specific code in the 10th edition of the International Classification of Diseases system (ICD10). The ICD10 guide recommends that patients with hepatic encephalopathy are classified as K72.9; hepatic failure, un-specified. Public Health England is working on raising the profile of hepatic encephalopathy with the Lancet Commission.

  • Rushanara Ali – 2015 Parliamentary Question to the Department of Health

    Rushanara Ali – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Rushanara Ali on 2015-02-20.

    To ask the Secretary of State for Health, how much Barts’ Trust has paid for locum staff in each of the last five years.

    Dr Daniel Poulter

    The information is not available in the format requested. Total earnings for locum doctors, at Barts Health NHS Trust for the period April 2012 to October 2014 are shown in the following table.

    April 2012 to October 2012

    November 2012 to October 2013

    November 2013 to October 2014

    All locum doctors

    £3,808,133

    £4,810,950

    £4,037,180

    Source: Health and Social Care Information Centre, Provisional NHS Staff Earnings Estimates.

    Notes:

    Data prior to April 2012, when the present merged Barts Health NHS Trust opened, are not available.

    These figures represent payments made using the Electronic Staff Record system to National Health Service staff who are employed and directly paid by NHS organisations.

  • Rushanara Ali – 2015 Parliamentary Question to the Department of Health

    Rushanara Ali – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Rushanara Ali on 2015-02-20.

    To ask the Secretary of State for Health, what public health grant was awarded to Tower Hamlets in each year from 2005-06 to 2013-14.

    Jane Ellison

    Tower Hamlets, in line with other local authorities, has only been in receipt of a public health ring fenced grant since 1 April 2013. In 2013/14 Tower Hamlets received a grant of £31,382,000.